CAG
ABMD

Crestwood Advisors Group’s Abiomed Inc ABMD Stock Holding History

Crestwood Advisors Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-280
Closed -$38K – 460
2017
Q1 		$38K Buy
+280
New +$32.5K ﹤0.01% 296

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Crestwood Advisors Group's ABMD Position: Q2 2017 in Review

Crestwood Advisors Group sold out of Abiomed Inc (ABMD) in Q2 2017, closing a stake of 280 shares — an estimated $38K sold.

Crestwood Advisors Group first reported a position in ABMD in Q1 2017 and held it in 1 quarter. The position peaked at $38K in Q1 2017. 303 funds tracked by Wall St. Rank hold ABMD as of Q2 2017.

  • Crestwood Advisors Group reported no remaining Abiomed Inc position as of Q2 2017 after selling out during the quarter.
  • Crestwood Advisors Group sold 280 Abiomed Inc shares in Q2 2017, an estimated $38K.
  • Crestwood Advisors Group first reported a position in Abiomed Inc in Q1 2017 and held it in 1 quarter.
  • Crestwood Advisors Group's Abiomed Inc position peaked at $38K in Q1 2017.
  • 303 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2017.

Based on Crestwood Advisors Group's 13F filing for Q2 2017, filed 31 Jul 2017.